Shaheen Tomah, MD

Dir. Clinical Development @altimmuneinc | Liver & Metabolic Diseases | ex-@harvardmed @JoslinDiabetes | Levantine Pathfinder | views=own=/=employer(s)

[Altimmune, Inc. @AltimmuneInc]

We're excited to announce positive topline results from our Phase 2 RECLAIM study evaluating our investigational balanced 1:1 glucagon/GLP-1 dual agonist in alcohol use disorder (AUD).

Learn more about the results and next steps: https://t.co/qasCsyuXYz

[Shaheen Tomah, MD @Tomah_MD]

ICYMI checkout our IMPACT trial results pub’ed in @TheLancet
Pemvidutide is the first incretin to show histological MASH resolution and weight loss at 24 wk.
@AASLDtweets @NoureddinMD @AlkhouriNaim @AltimmuneInc
https://t.co/omMKBVWnby

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

New @TheLancet - Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

https://t.co/g7dwo3gsTO

#LiverTwitter #MedTwitter

[Shaheen Tomah, MD @Tomah_MD]

@nntaleb From our groves in Beth Shbat ~34 km north from LB border (Abboudiye)

[Shaheen Tomah, MD @Tomah_MD]

@DrMakaryFDA commish on how you can know a lot by knowing what’s wrong. @GalienFdn

[Shaheen Tomah, MD @Tomah_MD]

@nntaleb Waist-to-height ratio and body roundness index more appropriate surrogates for central adiposity.

[Altimmune, Inc. @AltimmuneInc]

Today we hosted our virtual R&D Day where we shared updates and future development plans for #pemvidutide, our GLP-1/glucagon dual receptor agonist for #MASH as well as AUD and ALD.

Watch the full replay here: https://t.co/DV0ad0WgOW

[Shaheen Tomah, MD @Tomah_MD]

@nntaleb Probably

[CNBC's Fast Money @CNBCFastMoney]

Another obesity drug competitor?

@AltimmuneInc CEO Vipin Garg breaks down what's next for his company's experimental obesity drug pemvidutide, and what differentiates it from the rest of the field $ALT

https://t.co/glItwNlsNw

[Altimmune, Inc. @AltimmuneInc]

Today, we announced the completion of our End-of-Phase 2 meeting with the U.S. FDA and agreement on the design of a Phase 3 registrational program for #pemvidutide in the treatment of #obesity.
Learn more in the full release: https://t.co/y2De3De1Xq

[Shaheen Tomah, MD @Tomah_MD]

@nntaleb Makes a good case for an article “Abuse of Bivariate models in STATA”

[Daniel J Drucker @DanielJDrucker]

The search for healthy #weightloss continues with attention to % lean mass loss and functional outcomes. New body composition data for Pemvidutide, the GCG-GLP-1 co-agonist in humans with #obesity after 48 weeks @AltimmuneInc #EASD2024 @EASDnews

[Mazen Noureddin, MD, MHSc @NoureddinMD]

Thanks to @EASLnews for the invite👇🏼 to chat about exciting MOA and durgs in #MASH and #obesity with outstanding European 🌎colleagues .pls join us #livertwitter @AlkhouriNaim @RamyYounes9 @AleksanderKrag @AASLDtweets @AltimmuneInc @Tomah_Hawk @Merck @novonordisk @JHepatology

[Daniel J Drucker @DanielJDrucker]

Glucagon-GLP-1 co-agonists are emerging as interesting agents for metabolic liver disease. Here is a12 week dose ranging study for Pemvidutide https://t.co/Uvpvxp60g1

[Shaheen Tomah, MD @Tomah_MD]

@nntaleb Best Shawerma I’ve had in New England is “Mike’s Calzones and Deli” in PVD

[Ed Livingston @ehlJAMA]

DO GLP-1 Agonists Really Cause Eye Disease

There has been a huge amount of press about a report showing an association between the use of GLP-1 agonists and Nonarteritic anterior ischemic optic neuropathy (NAION)

https://t.co/IjBl0wN10a

Because of it being heavily promoted by JAMA, the article has an Altmetric score of 1982. However, despite wide dissemination of the study's conclusions, very few people actually read the article (only 3,918 downloads-consider the denominator here: 1 million physicians in the US and 10 million healthcare providers).

The conclusions should not be accepted without critical analysis of the study itself. There are limitations:

1) This disease occurs in patients with diabetes. GLP-1 drugs are generally used for more advanced cases of DM. There was no control for diabetes severity in the study. It is likely that the NAION was more likely to occur in patients with more severe DM - the same population more likely to be prescribed GLP-1 agonists. The lack of control for DM severity is a major limitation and probably should negate any conclusion about the relationship between GLP-1 agonists and eye disease.

Note form the limitations section: "our study also is
limited in that the severity of confounding factors could not be adequately assessed,"

At a minimum, this analysis should have controlled for HgA1c levels.

2) The study had an extremely small number of patients and the population was not representative of the average patient with DM. Of 979 eligible patients, only 32 had NAION. Of these 27 were treated with semaglutide and 5 with other drugs. Semaglutide is not a 1rst line treatment for DM. That the majority of patients in this study were being treated with this drug suggests that the patients had severe, probably poorly controlled DM. Note #1 above- the statistical analysis for this study did not include control for DM severity.

See: DM Standards of Care from the ADA: https://t.co/hFlR9wPj25
The first line treatment for DM is diet control, weight loss and metformin. GLP-1 agonist drugs are advised when these fails or if treating patients with a high risk for DM complications.

2) From the methods: Propensity matching was used to assess whether prescribed semaglutide was associated with NAION in patients with type 2 diabetes (T2D) or overweight/obesity. Propensity methods do not balance unmeasured risk variables or confounders. They also result in loss of information and power by excluding patients who cannot be matched. In the study, there were 32 patients with a NAION event. Of these only 23 were studied after a propensity score match and 18 after propensity score and exact matching. How the excluded patients might affect the results is unknown.

3) As mentioned in a previous tweet (X?), the confidence intervals for the study results were huge. This happens when there are too few events to reliably analyze.

From the abstract:

"A Cox proportional hazards regression model showed higher risk of NAION for patients receiving semaglutide (hazard ratio [HR], 4.28; 95%CI, 1.62-11.29); P < .001)."

"A Cox proportional hazards regression model showed a higher risk of NAION for patients prescribed semaglutide (HR, 7.64; 95%CI, 2.21-26.36; P < .001)."

As a general rule, findings with very large confidence intervals should be considered suspect-In other words, there is not a lot of confidence in the results.

The figure got a lot of attention. Note that the effect was magnified by an insert showing survival probabilities between 90 and 100. the figure looks dramatic because of this. this got the public's attention but is misleading. There are no confidence intervals in this graph to show how well separated the groups survival really was. Given the very small numbers of patients, the CIs probably showed significant overlap.

The major problem here is that this research really does not show an association between NAION and GLP-1 drugs-Yet, it was widely summarized by the press and made its rounds through social media. It came to my attention when someone sent e the article suggesting that our group look at this problem in more detail.

It would be nice if there was more critical review of findings like these before the public absorbed the conclusions.

I am sure there is more to this article than I picked up on and look forward to more discussion about it.

Social media is probably a better venue for peer review for scientific findings than journals-This comes from someone who was a JAMA editor for many years. SM enables broader audience to draw upon for comment and facilitates expression of a diversity of views.

[Shaheen Tomah, MD @Tomah_MD]

MOMENTUM: Pemvidutide Boasts "Class-Leading" Lean Mass Preservation with Weight Loss https://t.co/zEAVfuOmsn via @HCPLiveNews

[Daniel J Drucker @DanielJDrucker]

#ADA2024 @VertexPharma revealed that all 12 patients who received the full dose of VX-880 #islets #stemcells as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 –3 pts achieved #insulin independence https://t.co/u2TzEUyXjR

[Altimmune, Inc. @AltimmuneInc]

Today, our Associate Director of Clinical Development, Shaheen Tomah, M.D., will present on the promise of #GLP1/#glucagon to produce cardiovascular benefits for #obesity and #MASH patients at the TIDES USA Conference. More here: https://t.co/jhAxbmLnPX

@TIDESInforma #TIDESUSA

[Elliot Tapper @ebtapper]

Stephen Harrison had a massive, positive, impact on the field. He produced landmarks in the epidemiology of NAFLD/MASLD, non-invasive testing, and he lead the trial that brought us the first FDA-approved drug

[Shaheen Tomah, MD @Tomah_MD]

@nntaleb BMI doesn’t account for body composition or fat distribution, a major biomarker of metabolic health. Waist-to-height ratio factors in central adiposity (&gt;0.5) often associated w/ insulin resistance.